ProCE Banner Activity

NATALEE: Subgroup Analysis of Adjuvant Ribociclib + NSAI vs NSAI Alone in Patients With Stage II/III Node-Negative HR+/HER2- EBC

Conference Coverage
Slideset

Analysis of the subgroup of patients with stage II/III node-negative HR+/HER2- disease enrolled on the phase III NATALEE trial showed consistent efficacy benefit and a manageable safety profile for ribociclib + NSAI vs NSAI alone.

Released: June 02, 2024

Expiration: June 01, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Novartis Pharmaceuticals Corporation.

AstraZeneca

Daiichi Sankyo, Inc.

Novartis Pharmaceuticals Corporation